Monitor for future Form 4 filings that may indicate option exercises or stock sales, particularly as vesting dates approach in 2026-2027. The mutual appointment of attorneys-in-fact suggests coordinated compliance procedures among executives.
Price Chart
Executive Summary
Kailera Therapeutics executives Scott Akamine and Frank Clyburn filed initial Form 3 statements disclosing stock options and established powers of attorney for SEC filings. The filings reveal option grants totaling over 720,000 shares with multi-year vesting schedules, indicating ongoing executive compensation arrangements.
Key Facts
- Scott Akamine, Chief Legal Officer, reported options to purchase 551,562 shares of common stock with exercise prices between $5.25 and $7.24, vesting through 2026-2027
- Frank Clyburn, board member, reported options to purchase 170,194 shares at $7.24 exercise price, vesting starting October 2026
- Both executives appointed attorneys-in-fact (including each other) to handle SEC filings related to securities transactions
- Filings were submitted on April 16, 2026, but option grants appear to have been made in late 2025
Financial Impact
Undisclosed value of stock option grants to executives, with total potential dilution of approximately 721,756 shares
Risk Factors
- Future option exercises could result in share dilution
- Potential for insider selling once options vest
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (KLRA) — Batch item 1 | 0001193125-26-159645 |
| Document: 0001193125-26-159645-index-headers.html | 0001193125-26-159646 |
| Document: 0001193125-26-159645-index.html | 0001193125-26-159645 |
| Document: 0001193125-26-159645.txt | 0001193125-26-159645 |
| 3 Filing (KLRA) — Batch item 5 | 0001193125-26-159646 |
| Document: 0001193125-26-159646-index-headers.html | 0001193125-26-159645 |
| Document: 0001193125-26-159646-index.html | 0001193125-26-159645 |
| Document: 0001193125-26-159646.txt | 0001193125-26-159645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access